Rite Aid lowers guidance

• Rite Aid (NYSE:RAD) cuts its outlook on FY15 EPS to a range of $0.22-$0.33 vs. $0.30-$0.40 prior and $0.34 consensus.
• The company says its pharmacy margin will be negatively impacted from new generic drugs and the loss of exclusivity on other generics.
• Same store sales are expected to rise 3% to 4% for the fiscal year.
• RAD -8.4% premarket